- Company
- Clinical data on use of Repatha in Koreans revealed
- by Son, Hyung-Min Apr 30, 2024 05:49am
- Amgen's dyslipidemia drug Repatha (evolocumab) has demonstrated LDL-cholesterol reduction in an additional trial conducted on Koreans. Based on the verified results, Amgen Korea emphasized the need for early access to Repatha for high-risk patients whose LDL cholesterol is uncontrolled with statins. Amgen Korea held a press conference at
- Company
- Evolving ADC…pharma companies explore new DAC platform
- by Son, Hyung-Min Apr 30, 2024 05:49am
- New forms of technology utilizing the antibody-drug conjugate (ADC) are global trends. One such form is the degrader-antibody conjugate (DAC), a conjugate with the ADC merged with targeted protein degradation (TPD). According to industry sources on the 27th, Biotech companies, including Orum Therapeutics, Nurix Therapeutics, Prelude Therapeut
- Policy
- New PVA operation system will be implemented from May
- by Lee, Tak-Sun Apr 30, 2024 05:49am
- The detailed operation standards for the Price-Volume Agreement negotiations will change drastically from May. The reduction rate will be applied differently depending on the amount of each drug’s insurance claims, and products with annual claims of less than KRWk 3 billion will be excluded. In addition, the discount rate of drugs that ha
- Policy
- Gov’t discloses draft for overseas drug price reevals
- by Lee, Tak-Sun Apr 29, 2024 05:50am
- The Korean government presented a draft of its plan during a meeting for the foreign drug price comparison reevaluations that was held on the 26th. The government’s foreign drug price comparison reevaluation was planned by the government to adjust the price of off-patent drugs by comparing their price to the upper limit of A8 countries (Jap
- Company
- Patients request Leqembi’s reimb even before approval
- by Eo, Yun-Ho Apr 29, 2024 05:50am
- More specifically, the drug is indicated for ‘slowing progression of mild cognitive impairment (MCI) and mild dementia due to&160;Alzheimer's disease.’ Leqembi has been proven to reduce the rate of disease progression and slow cognitive decline by selectively binding to amyloid beta (Aβ) aggregates, which are a known cause of Alzheime
- Opinion
- [Reporter’s View] Patients are left to suffer amid dispute
- by Lee, Jeong-Hwan Apr 29, 2024 05:50am
- It has been 3 months since the doctors and the government failed to see eye to eye on the government’s plan to expand medical school admissions by 2,000 students. The prolonged dispute has intensified animosity towards each other. The doctors have criticized the Minister and Vice Minister of Health and Welfare, Kyoo-hong Cho and Minsoo P
- Policy
- Jardiance under review for expanding reimb to kidney disease
- by Lee, Tak-Sun Apr 29, 2024 05:49am
- 'Jardiance tab (empagliflozin, Boehringer Ingelheim Korea),' SGLT-2 class of treatment, is considered for expanding reimbursement to kidney disease, in addition to its current reimbursement for diabetes and cardiac failure. As Forxiga, a competing drug in the same class as Jardiance, is expected to withdraw from the Korean market in the
- Company
- After 9 years, greenlight for 'Ilaris' reimbursement likely
- by Eo, Yun-Ho Apr 29, 2024 05:49am
- In about nine years since its approval in South Korea, the orphan drug 'Ilaris' is heading toward reimbursement listing. Novartis’ continued effort has shined. In February, Ilaris (canakinumab), a drug used to treat periodic fever syndromes (PFS), received a conditional pass decision from the Drug Reimbursement Evaluation Committee (DREC
- Company
- A change in the DPP4 diabetes market worth KRW 600 billion
- by Kim, Jin-Gu Apr 26, 2024 05:48am
- The market for DPRR-4 inhibitor class diabetes treatment, valued at KRW 600 billion annually, is undergoing a significant shift. Following the expiration of substance patents for major original products, generics have been launched, rapidly expanding their prescriptions. At the same time, the growth of original products is experiencing a sl
- Company
- ‘HTL is the best global partner for Korean companies'
- by Lee, Seok-Jun Apr 26, 2024 05:48am
- There is an easy way for domestic pharmaceutical companies wishing to go global: meet a partner that has extensive experience in entering the global market. The companies can speed up their global expansions by receiving the partner's know-how and minimizing trial and error. Time is money. Especially in the rapidly changing pharmaceutical and
